Back to News

More Than 450 Companies Adopt ³Ô¹Ï±¬ÁÏ eTMF for Improved Trial Efficiency and Inspection Readiness

Companies modernizing TMF management to drive automation and speed

BARCELONA, Spain ¡ª 5 June 2023 ¡ª As the industry advances clinical operations, adopting applications on a unified platform is a top priority to increase study efficiency and compliance. More than 450 biopharma companies¡ªincluding 18 of the top 20 pharmas and 4 of the top 6 CROs¡ªuse ³Ô¹Ï±¬ÁÏ eTMF to automate trial processes and improve information exchange across stakeholders.

As regulatory and trial complexity grows, more companies are increasing transparency and inspection readiness with ³Ô¹Ï±¬ÁÏ eTMF. ³Ô¹Ï±¬ÁÏ Systems (NYSE: VEEV) is helping organizations address critical TMF challenges with innovations, including:

  • TMF Bot to automate document classification for faster, more efficient processing and improved accuracy. TMF Bot has classified more than one million documents, saving customers tens of thousands of hours in processing time.
  • Seamless connection between ³Ô¹Ï±¬ÁÏ eTMF and ³Ô¹Ï±¬ÁÏ RIM to increase efficiency and collaboration between clinical and regulatory teams. Customers have shared more than 40,000 documents across more than 600 studies.
  • TMF Transfer to enable the quick exchange of TMF documents between sponsors and CROs. This has eliminated hundreds of hours in manual end-of-study migrations.
  • ³Ô¹Ï±¬ÁÏ Site Connect to streamline information exchange with research sites. Customers have exchanged more than 100,000 documents across more than 1,000 connected study sites.

¡°We¡¯re excited to continue partnering with customers to advance TMF for more efficient, compliant clinical trials,¡± said Jason Methia, vice president, ³Ô¹Ï±¬ÁÏ Clinical Operations strategy. ¡°By delivering ³Ô¹Ï±¬ÁÏ eTMF innovations, we¡¯re tackling challenges that can significantly streamline study processes and move the industry forward.¡±

³Ô¹Ï±¬ÁÏ eTMF is part of ³Ô¹Ï±¬ÁÏ Clinical Platform, the industry¡¯s first cloud platform that unifies clinical data management and operations. ³Ô¹Ï±¬ÁÏ Clinical Platform includes ³Ô¹Ï±¬ÁÏ eTMF, ³Ô¹Ï±¬ÁÏ CTMS, ³Ô¹Ï±¬ÁÏ Site Connect, ³Ô¹Ï±¬ÁÏ Payments, ³Ô¹Ï±¬ÁÏ Study Start-up, ³Ô¹Ï±¬ÁÏ Study Training, ³Ô¹Ï±¬ÁÏ EDC, ³Ô¹Ï±¬ÁÏ CDB, , and ³Ô¹Ï±¬ÁÏ ePRO.

Additional Information
For more on ³Ô¹Ï±¬ÁÏ eTMF, visit: veeva.com/eu/eTMF
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:

About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world¡¯s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

³Ô¹Ï±¬ÁÏ Forward-looking Statements
This release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ¡¯s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2023, which you can find (a summary of risks which may impact our business can be found on pages 37 and 38), and in our subsequent SEC filings, which you can access at .

###

Contact:
Jeremy Whittaker
³Ô¹Ï±¬ÁÏ Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Contact:
Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com

Powerful Community, Fresh Ideas

Copenhagen | 28-29 May, 2026

Learn more